List of Excipients in Branded Drug GATTEX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Takeda Pharmaceuticals America Inc	GATTEX	teduglutide	68875-0101	HISTIDINE	2026-05-16
Takeda Pharmaceuticals America Inc	GATTEX	teduglutide	68875-0101	MANNITOL	2026-05-16
Takeda Pharmaceuticals America Inc	GATTEX	teduglutide	68875-0101	SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE	2026-05-16

GATTEX Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

GATTEX (teduglutide) is a once-daily subcutaneous peptide therapy for adults and children with short bowel syndrome who depend on parenteral support. Its excipient strategy is deliberately simple: a lyophilized, single-dose vial containing teduglutide with histidine, mannitol and phosphate-buffer components, reconstituted with sterile water before administration. The largest commercial opportunities are not new excipients alone. They are improved stability, ready-to-use delivery, pediatric usability, reduced preparation burden and differentiated combination products.

GATTEX has meaningful commercial protection because it treats a rare, high-cost condition with limited alternatives. Excipient innovation could extend product differentiation after core substance patents and regulatory exclusivity weaken, but formulation changes would need to overcome manufacturing, stability, device and clinical-bridging requirements.

What is GATTEX and how does its formulation work?

GATTEX contains teduglutide, a recombinant analogue of human glucagon-like peptide-2. Teduglutide promotes intestinal mucosal growth and improves intestinal absorption in patients with short bowel syndrome. The product is administered by subcutaneous injection once daily.

The U.S. product is supplied as a sterile, preservative-free lyophilized powder in a single-dose vial. The labeled formulation uses:

Component	Formulation role
Teduglutide	Active peptide
L-histidine	Buffering and peptide-stability support
Mannitol	Bulking agent and lyophilization support
Sodium phosphate monobasic monohydrate	Buffer component
Sodium hydroxide or hydrochloric acid	pH adjustment
Sterile water for injection	Reconstitution diluent

The reconstituted solution is intended for immediate use and is not designed as a conventional multi-dose injectable. The label places practical limits on storage after reconstitution, which creates a central formulation opportunity: extending in-use stability without increasing aggregation, oxidation, microbial risk or injection-site burden.[1]

What excipients protect the GATTEX formulation?

The current excipient system is a conventional peptide lyophilization platform. Its commercial value comes from compatibility with the active peptide and from a manufacturing process that produces a stable cake for reconstitution.

Histidine and phosphate buffer

Histidine and phosphate control formulation pH. For peptide products, pH selection affects solubility, aggregation, deamidation and chemical degradation. A buffer system can improve short-term stability but can also create risks during freezing and drying. Phosphate may crystallize or partition during lyophilization, making cycle development and scale-up important.

A competing formulation could examine alternative buffer systems such as acetate, citrate, succinate or histidine-only systems. The commercial objective would be to improve one or more of the following:

• Reconstitution speed
• Long-term stability
• Resistance to agitation
• Reduced particulate formation
• Compatibility with liquid storage
• Lower injection volume

A buffer substitution would not automatically create a strong market position. The sponsor would need comparative stability data, container-closure studies and regulatory support demonstrating that the new formulation has no clinically relevant impact on exposure or immunogenicity.

Mannitol

Mannitol acts primarily as a bulking agent and contributes to the physical structure of the lyophilized cake. It can improve visual appearance, handling and reconstitution performance.

Mannitol-based systems may still require optimization because crystallization behavior can affect peptide stability. Alternative bulking agents, including sucrose, trehalose or glycine, could be evaluated where they improve cake structure or protect the peptide during freezing and drying.

Trehalose and sucrose are particularly relevant for peptide stabilization because they can replace water around the peptide during drying. Their use may create a stronger technical rationale for a liquid or less aggressively dried product, but they can also introduce viscosity, residual-moisture and reconstitution considerations.

Preservative-free single-dose design

The absence of a preservative reduces concerns about local tolerability and compatibility with a sensitive peptide. It also limits the product to single-use handling. A multi-dose product would require a validated antimicrobial-preservative system, a different container-closure strategy and clinical assessment of injection-site tolerability.

A preservative-free multi-dose device could be commercially attractive but technically difficult. The product would need to maintain sterility across repeated access while preventing peptide adsorption, aggregation and dose loss. Cartridge and autoinjector systems may offer more practical paths than a conventional multidose vial.

What formulation patents protect GATTEX?

GATTEX protection is likely divided among active-ingredient patents, formulation and manufacturing patents, use patents and regulatory exclusivity. The strongest commercial barriers historically have been associated with teduglutide itself, its therapeutic use in short bowel syndrome and the specialized manufacturing of a recombinant peptide.

Protection category	Relevance to GATTEX	Commercial effect
Teduglutide composition patents	Protect the peptide or related sequence	Can block direct substitution
Method-of-use patents	Cover treatment of short bowel syndrome and reduction of parenteral support	May limit labeled generic use
Formulation patents	Cover pH, excipients, stability or dosage forms	Can delay or narrow follow-on entry
Manufacturing patents	Cover recombinant production, purification or peptide handling	Raise technical entry costs
Device patents	Cover injection or reconstitution systems	Protect user-experience differentiation
Orphan-drug exclusivity	Seven years for the eligible U.S. indication	Blocks approval of the same drug and indication
Pediatric exclusivity	Six-month extension when granted	Extends qualifying regulatory protections

The FDA approved GATTEX in December 2012 for adult patients with short bowel syndrome who are dependent on parenteral support. The FDA later expanded the indication to pediatric patients in 2019.[2,3] The original U.S. orphan-drug exclusivity period therefore expired before the pediatric expansion, while pediatric exclusivity could extend applicable listed protections by six months if awarded.

A precise patent-by-patent freedom-to-operate analysis requires current FDA Orange Book records, USPTO status, district-court dockets and any terminal-disclaimer calculations. Patent expiration dates should not be inferred solely from publication dates because patent-term adjustment, patent-term extension and disclaimers can change the effective blocking period.

What is the Orange Book status of GATTEX?

GATTEX is listed by FDA as an approved drug product under NDA 203441. It is not a conventional monoclonal-antibody biologic, so biosimilar analysis is less direct than for products approved under the Public Health Service Act. A follow-on applicant would more likely evaluate an ANDA or 505(b)(2) strategy, depending on the reference product, peptide characterization, manufacturing process and formulation differences.[4]

The Orange Book is commercially important because listed patents can trigger a 30-month stay after a Paragraph IV certification and a patent-infringement action. The main entry routes are:

1. An ANDA asserting bioequivalence and addressing listed patents.
2. A 505(b)(2) application relying partly on GATTEX data while using a new formulation, device or dosing presentation.
3. A full development program for a distinct teduglutide product.
4. A different intestinal rehabilitation therapy that competes clinically without copying GATTEX.

For a complex peptide, 505(b)(2) may be more commercially realistic than a straightforward ANDA if the proposed product changes excipients, concentration, route, reconstitution, device or storage conditions.

When does GATTEX lose exclusivity?

GATTEX has already passed its original U.S. orphan exclusivity period for the adult indication. That does not mean unrestricted generic entry. Commercial entry remains dependent on patent status, FDA approval pathway, manufacturing capability and the ability to demonstrate equivalent performance.

Event	Timing or status
U.S. approval	December 2012
Adult short bowel syndrome orphan exclusivity	Approximately seven years from approval
Pediatric indication expansion	2019
Pediatric exclusivity potential	Six months, if granted
Current entry assessment	Patent, regulatory and manufacturing analysis required
Primary commercial barrier	Complex peptide product with rare-disease economics

The absence of a conventional small-molecule generic does not indicate that GATTEX is immune from competition. It means the likely entrant must solve more technical problems. These include peptide identity, impurity profile, potency assay, aggregation control, sterile manufacturing and device performance.

What excipient strategies could create a commercial opportunity?

Ready-to-use liquid GATTEX alternative

A liquid formulation could eliminate reconstitution and reduce preparation errors. The opportunity is strongest for pediatric patients, caregivers and home-infusion settings.

Key technical risks include:

• Teduglutide degradation during refrigerated or room-temperature storage
• Aggregation at higher concentration
• Adsorption to syringe, cartridge or tubing surfaces
• Oxidation and deamidation
• Increased injection volume or viscosity
• Container-closure extractables and leachables

A successful liquid product could support a 505(b)(2) application and obtain device or formulation patents. Its value would be greater if it delivered a commercially meaningful shelf-life, such as a stable refrigerated product with limited room-temperature excursions.

Autoinjector or cartridge presentation

GATTEX requires patient or caregiver preparation. A prefilled syringe, cartridge or autoinjector could improve adherence and reduce handling steps.

The excipient program would need to work with:

• Silicone oil exposure
• Needle and elastomer compatibility
• Low-dose accuracy
• Delivery-force requirements
• Device dead volume
• Product residence time in the primary container

The combination of formulation and device may provide stronger differentiation than an excipient change alone. A device patent could protect the presentation even after a formulation patent becomes vulnerable.

Longer in-use stability

The current reconstituted product is intended for prompt use. A formulation that remains stable after reconstitution could reduce wastage and provide flexibility for patients who manage daily injections.

Commercial value would depend on proving:

• Chemical stability
• Physical stability
• Sterility maintenance
• Particulate control
• Consistent potency
• No clinically meaningful change in immunogenicity

An extended in-use product could also support specialty-pharmacy distribution and reduce replacement of improperly prepared doses.

Pediatric-centered formulation

The pediatric market creates a separate opportunity because children may require weight-based dosing and smaller injection volumes. A higher-concentration formulation could reduce injection volume, but concentration changes can increase aggregation and viscosity.

Potential differentiation includes:

• Lower-volume dosing
• Simplified weight-based administration
• Prefilled pediatric-dose presentations
• Reduced preparation time
• Easier storage and transport
• More consistent dose measurement

A pediatric formulation would require careful control of dosing flexibility. A single fixed-dose autoinjector may be unsuitable if patients need frequent dose adjustments based on body weight.

Alternative stabilizers and surfactants

Surfactants such as polysorbates or poloxamers could reduce interfacial aggregation, particularly in liquid formulations and devices. They can also introduce degradation products, peroxide-related oxidation or formulation variability.

Other excipients, including trehalose, sucrose, glycine and methionine, could be screened for improved peptide protection. The strongest intellectual-property position would likely come from a defined combination of excipients, pH range, concentration and storage condition rather than from the use of a widely known excipient in isolation.

How strong is the GATTEX patent estate?

The estate is commercially stronger than a simple excipient count suggests because GATTEX combines a rare-disease indication, a recombinant peptide, specialized sterile manufacturing and a dosing regimen tied to clinical outcomes.

Strengths

• High technical burden for peptide characterization
• Limited direct clinical alternatives
• Difficult-to-replicate manufacturing and impurity control
• Potential use patents tied to reduction of parenteral support
• Regulatory and reimbursement complexity
• Patient dependence on a reliable specialty product

Vulnerabilities

• Original orphan exclusivity has expired
• Teduglutide is a defined peptide rather than an inherently uncopyable biologic
• Formulation substitutions may enable 505(b)(2) entry
• A new device can bypass some vial-based limitations
• Rare-disease revenue can justify a focused specialty entrant
• Method-of-use patents may be vulnerable to claim construction and invalidity challenges

The formulation estate is most defensible when it demonstrates an unexpected stability or usability advantage. Broad claims covering common buffers, sugars or bulking agents are more exposed to obviousness challenges than narrow claims tied to specific concentration ranges, stability results and device conditions.

Which companies could challenge GATTEX?

Takeda is the commercial owner of GATTEX in the United States following its acquisition of NPS Pharmaceuticals. Potential challengers include:

• Specialty pharmaceutical companies developing 505(b)(2) peptide products
• Generic manufacturers with complex injectable capabilities
• Contract development and manufacturing organizations with sterile lyophilization capacity
• Device companies partnering with peptide developers
• Intestinal-failure specialists developing non-teduglutide therapies

A direct competitor would need to demonstrate a clinically credible reduction in parenteral nutrition or fluid dependence. A product with equivalent efficacy but materially easier administration could compete even without a lower price.

Biosimilar competition is less likely to be the immediate pathway than generic or 505(b)(2) competition because GATTEX is regulated as an NDA product rather than a typical biologic license application. The practical distinction is important: the competitive framework will depend on FDA’s classification of the proposed follow-on and the level of clinical evidence required.

What patent litigation and settlement risks affect GATTEX?

A Paragraph IV filing could produce litigation over:

• Teduglutide composition claims
• Recombinant production methods
• Lyophilized formulations
• Reconstitution and storage conditions
• Short bowel syndrome treatment methods
• Pediatric dosing or administration claims

A settlement could include a licensed entry date, a formulation carve-out, supply terms, or restrictions on pediatric and adult indications. In rare diseases, settlements may also incorporate authorized-generic supply or co-promotion arrangements.

No commercial assessment should assume that an Orange Book patent automatically blocks entry through its full listed term. The actual risk depends on claim scope, enforceability, litigation timing and whether the challenger can design around the asserted claims.

How does GATTEX compare with competing short bowel syndrome therapies?

Therapy	Active approach	Excipient opportunity	Competitive position
GATTEX	Teduglutide, GLP-2 analogue	Liquid stability, device, pediatric dosing	Established targeted therapy
Parenteral nutrition	Nutritional support	Bag stability and compatibility	Essential but burdensome
Surgical rehabilitation	Anatomical correction	Limited excipient relevance	Patient-specific
Antidiarrheal and antisecretory therapy	Symptom control	Oral dosage-form optimization	Usually supportive rather than substitutive
Future intestinal-growth therapies	Mechanism-dependent	Delivery and stability differentiation	Potential direct competition

GATTEX’s commercial advantage is tied to reducing dependence on parenteral support rather than merely treating symptoms. An entrant that cannot demonstrate a comparable effect on parenteral nutrition volume, frequency or duration would have difficulty replacing the product.

What revenue exposure and licensing opportunities exist?

GATTEX has a concentrated but valuable market. Patients with short bowel syndrome are few relative to mainstream chronic diseases, yet treatment costs are high and therapy is specialized. The commercial opportunity is strongest in products that reduce total treatment friction.

Potential licensing targets include:

• Stabilizer systems for liquid teduglutide
• Lyophilization-cycle technology
• Prefilled syringe or autoinjector platforms
• Low-dose peptide delivery systems
• Container-closure systems that reduce adsorption
• Pediatric dose-management platforms
• Sterile fill-finish and peptide analytics
• Authorized-generic or regional commercialization rights

A formulation license would be more attractive if it provides a measurable advantage in room-temperature stability, reconstitution time, dose accuracy or device compatibility. A basic excipient substitution without clinical or manufacturing benefit is unlikely to support premium economics.

Geographic opportunities differ. The United States offers the highest value but also the most developed patent and regulatory scrutiny. Europe and Japan may provide opportunities for localized licensing, device adaptation and specialty distribution. Global expansion requires evaluation of local orphan-drug rules, supplementary protection certificates, pediatric requirements and formulation-specific patent coverage.

Key Takeaways

• GATTEX uses a simple lyophilized peptide formulation based on histidine, mannitol and phosphate-buffer components.
• The leading commercial opportunity is a ready-to-use liquid, prefilled or autoinjector presentation.
• Excipient changes should target stability, reconstitution, injection volume and pediatric usability.
• Original orphan exclusivity has expired, but patent, manufacturing and regulatory barriers remain relevant.
• A 505(b)(2) pathway may be more practical than a conventional ANDA for a differentiated formulation or device.
• Biosimilar competition is less directly relevant than complex-generic and 505(b)(2) competition.
• The strongest formulation patents will likely require defined excipient ranges, pH, concentration, storage conditions and demonstrated stability advantages.
• Licensing value is highest for technologies that reduce preparation burden or enable liquid storage without compromising peptide quality.

FAQs About GATTEX Excipients and Commercial Strategy

What is the main excipient opportunity for a GATTEX competitor?

The main opportunity is a stabilizing formulation that permits liquid, ready-to-use storage while preserving teduglutide potency and limiting aggregation.

Can GATTEX be reformulated as a prefilled syringe?

Potentially, but the formulation must address peptide adsorption, container compatibility, dose accuracy, device dead volume, viscosity and stability during storage.

Is a GATTEX excipient change enough to obtain a new patent?

Usually, a routine excipient substitution is vulnerable to obviousness challenges. Stronger protection requires a defined formulation with unexpected stability, usability or delivery results.

Would a GATTEX follow-on be a generic or biosimilar?

A follow-on could be evaluated under an ANDA or 505(b)(2) pathway. Biosimilar treatment is less likely because GATTEX is an NDA-approved peptide product rather than a conventional biologic reference product.

Which GATTEX formulation improvement has the highest market value?

A stable, low-volume, ready-to-use pediatric-compatible presentation would likely have the highest commercial value because it could reduce preparation burden, improve adherence and differentiate the product after core exclusivity declines.

References

1. U.S. Food and Drug Administration. (2024). GATTEX (teduglutide) prescribing information.
2. U.S. Food and Drug Administration. (2012). FDA approves Gattex to treat short bowel syndrome.
3. U.S. Food and Drug Administration. (2019). FDA approves Gattex for pediatric patients with short bowel syndrome.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.